A Five‐Year Prospective, Randomized, Open‐Label Study of Standard‐Dose Versus Low‐Dose Prolonged‐Release Tacrolimus With or Without Angiotensin‐Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation
Patients randomized to LOW TAC with renin-angiotensin system (RAS) blockade had similar outcomes at 5 years as patients treated with STD TAC with or without RAS blockade, whereas those randomized to LOW TAC without RAS blockade showed a non-significant trend towards more rejections and dnDSA TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00933231.
Authors
- Jean‐Luc Wolff
- Felix‐Mauricio Monroy‐Cuadros
- Peter Nickerson (ORCID: https://orcid.org/0000-0002-7393-7799)
- Lynne Senécal (ORCID: https://orcid.org/0000-0002-7629-9980)
- Jason J. Schwartz (ORCID: https://orcid.org/0000-0002-7912-537X)
- D. Rush
- Anthony M. Jevnikar (ORCID: https://orcid.org/0000-0002-3374-8758)
- Marcelo Cantarovich (ORCID: https://orcid.org/0000-0002-4766-3333)
- Azim S. Gangji (ORCID: https://orcid.org/0000-0003-0131-8718)
- Patricia Campbell (ORCID: https://orcid.org/0000-0002-1909-4807)
- Isabelle Houde
- M Pâquet (ORCID: https://orcid.org/0000-0002-0606-617X)
- G. V. Ramesh Prasad (ORCID: https://orcid.org/0000-0003-1576-7696)
Institutions
- St. Michael's Hospital (CA)
- London Health Sciences Centre (CA)
- McGill University Health Centre (CA)
- Centre Hospitalier Universitaire de Sherbrooke (CA)
- Health Sciences Centre (CA)
- Foothills Medical Centre (CA)
- University of Alberta Hospital (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Hôpital Notre-Dame (CA)
- Hôtel-Dieu de Québec (CA)
- Astellas Pharma (United States) (US)
- St. Joseph’s Healthcare Hamilton (CA)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1111/ctr.70067
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Astellas Pharma